Summit Therapeutics plc (SMMT) Social Stream
SUMMIT THERAPEUTICS INC (SMMT) Price Targets From Analysts
The tables below show the price targets and recommendations analysts covering SMMT.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| NA | 1 | $NA | $NA | $NA | $3.06 | NA% |
Price Target Last Issued NA NA, NA
The Trend in the Analyst Price Target
SMMT's average price target has moved down $0 over the prior 58 days.
500 - Internal server error
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|
SMMT Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 3 | 0 | 0 | 1 | 0 | 0 | 1 |
Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.
- To contextualize these metrics, consider that out of all US stocks, SUMMIT THERAPEUTICS INC's number of analysts covering the stock is greater than practically none of them.
- To contextualize these metrics, consider that out of stocks in the small market cap category, SUMMIT THERAPEUTICS INC's variance in analysts' estimates is lower than just about 100% of them.
- In the context of stocks in the small market cap category, SUMMIT THERAPEUTICS INC's average analyst price target is greater than practically none of them.
- In terms of how SUMMIT THERAPEUTICS INC fares relative to stocks in the small market cap category, note that its upside potential (average analyst target price relative to current price) is higher than practically none of that group.
In the Pharmaceutical Products industry, CARA, OCUL, and ARDX are the three stocks most similar to SUMMIT THERAPEUTICS INC regarding the price target and analyst recommendation information presented here.
View All Top Stocks by Price Target
Is SMMT a Buy, Hold or Sell? See the POWR Ratings now!